Herpes Zoster Infection PDF
Herpes Zoster Infection PDF
Herpes Zoster Infection PDF
Definition
Varicella-zoster virus (VZV), also known as Human Herpes Virus III (HHVIII), is a
member of the herpes virus group. As all the other viruses from this group, VZV can
manifests itself as a recurrent infection. After entering the body and causing primary
infection, varicella-zoster virus remains latent in the neurons of sensory ganglion,
especially dorsal roots of ganglion of the spinal nerves and extramedullar ganglion of
the cranial nerves. Reactivation of the VZV infection is easily triggered by immune
suppression. VZV infection is common in elder persons, immunocompromised or HIV
positive individuals, and patients affected by malignant blood dyscrasias, malignant
tumours, or undergoing immunosupressive therapy and radiotherapy.
Epidemiology
Varicella (chickenpox) is the primary infection of VZV and it is very common among
children of both sexes. Herpes zoster (shingles) is the recurrent form of infection and
occurs in the 3-5% of population, mainly among older individuals and
immunocompromised. One percent of the persons who are 80 years old may have
an infection during the period of one year. In 10% of HIV positive patients, HIV
disease starts with herpes zoster infection in the oral cavity as an oral opportunistic
infection. Reactivation of infection is infrequent in younger people and children.
Postherpetic neuralgia, a significant pain or dysaesthesia present 3 or more months
after herpes zoster, approximately 10–20% of zoster patients of all ages are affected,
but frequency increases with age.
Clinical manifestations
Herpes zoster (HZ) in the oral cavity results from the involvement of second and third
branch of the trigeminal nerve.
HZ develops 2-4 days after prodromal period, manifesting itself with general
symptoms, such as fever, weakness, fatigue, and neck stiffness. Paresthesia and
burning sensation in the region of the affected nerve are also frequent consequences
of the VZV infection. Characteristic sign of oral HZ is the presence of unilateral
vesicles that break rapidly, leaving small ulcers. On skin and lips, vesicle rupture can
result in erosions covered by pseudomembranes and haemorrhagic crusts. Oral
lesions without facial skin involvement are rather infrequent. Crusts and
pseudomembranes, developing during the first week of vesicle formation, usually
disappear in the second or third week. The patient is contagious from 48 hours
1
before vesicle formation, until oral lesions heal. It is possible that HZ occurs without
lesions ("herpes sine herpete" zoster without eruptions), when only neurological
symptoms are present. A frequent complication of HZ infection is postherpetic
neuralgia (PHN). PHN, which is not correlated with immune suppression, is
characterised by pain, paresthesia, hyposthesia or alodynia and can persist for
months and year. Neuralgic pain is frequently associated with sensory loss.
Etiopathogenesis
Following primary infection, the virus is latent in the neurons of the sensory ganglia
and reactivates itself as a consequence of immunodefficiency. The inflammation of
the ganglion is followed by hemorrhagic necrosis of the nerves together with a partial
necrosis of the ganglion. VZV affects neighbouring neurone ganglia and it might
affect several branches of the nerve. Viruses spreading through sensory parts of the
second and third branch of the trigeminal nerve, lead to the pathological changes in
the oral cavity. The viral presence further leads to the acantholysis in the prickle cell
of the epithelium and formation of the vesicles. Because of the subtle overlying layer,
vesicles rupture rapidly, leaving erosions. VZV damages peripheral nerves through
demineralisation, leading to sclerosis and degeneration.
Diagnosis
Diagnosis is made on the basis of clinical manifestations and subjective symptoms,
presence of the viral antigens as well as presence of antibodies against VZV.
Differential diagnosis of other viral infections is also possible so this infection must be
well documented. The best laboratory diagnostics are PCR and direct VZV
identification in the cell culture of human fibroblasts. The sample should be taken
from vesicle or serum. The presence of VZV is evidenced by direct
immunofluorescence of antibodies against VZV from the vesicle and up to 80% of the
VZV infections could be detected using this method. Serological findings are helpful
in recurrent VZV infections and show increased IgM, ten days after eruptions and
increased IgG and IgA four days after the eruptions. Serological tests which reveal
antibody titers might be useful in immunocompromised patients.
Treatment
Therapeutic regimens have become more efficient nowadays, especially when they
are applied 48-72 hours after the appearance of the oral lesions. Systemic intake of
antiviral agents is urgent in the patients who are older than 50 years of age, in
immunocompromised, and in all patients with infection of the head and neck region,
2
especially in those with HZ of the ophthalmic branch. In adult immunocompetent
subject of less than 50 years of age, symptomatic treatment is generally sufficient.
Acyclovir, valacyclovir, famciclovir or brivudin must be administered systemically.
Valacyclovir is proven to be more efficient when compared to the acyclovir. Brivudin
showed higher antiviral potential then acyclovir, valacyclovir and famciclovir. Brivudin
is also more easily administered (i.e. once a day during 7 days) and has no
nephrotoxic properties.
Systemic use of the antiviral drugs shortens the healing period and lessens the pain
symptoms together with prevention of other acute and/or chronic complications.
Treatment of PHN usually comprises of analgesics together with neuroactive agents
as well as with antiviral drugs. Corticosteroids administered systemically during the
first two weeks of the disease are helpful in the PHN prevention, but they should not
be given when PHN is already present. Some authors suggested combination of the
perilesional anesthetic and corticosteroid injections. Reports upon shortening of the
period of healing, but not PHN prevention have been documented. While treating
neuralgia, analgesics, neuroactive agents and B vitamin complex should be
administered. Some trials suggested that tryciclic antidepressants can be effective in
alleviating neuropatic pain.
3
Further reading
1 Greenberg MS, Glick M, Burket S. Oral Medicine, Diagnosis and Treatment,
10th edition. BC Decker Inc. Philadelphia 2003;pp. 55-57, 330-331.
2 Nurimiko T, Bowsher D. Somatosensory findings in postherpetic neuralgia. J
Neurol Neurosurg Psychiatry 1990; 3:135-41.
3 McKenzie CD, Gobetti JP. Diagnosis and treatment of orofacial herpes
zoster:report of cases. JADA 1990, 120:679-81.
4 Gross G, Schofer H, Wassilev S, et al. Herpes zoster guideline of the German
Dermatology Society (DDG). Am Fam Physician.2003; 67:757-62.
5 Cohen JI, Brunell PA, Straus SE, Krause PR. Recent advances in varicella-
zoster virus infection Ann Intern Med 1999; 130:922-32
Links
www.ihmf.org/default.asp International Herpes Management Forum (accessed on 1
July 2004).
www.herpes-foundation.org/ The American Herpes Foundation (accessed on 1 July
2004).